Applied Therapeutics Future Growth

Future criteria checks 2/6

Applied Therapeutics is forecast to grow earnings and revenue by 42.1% and 59% per annum respectively while EPS is expected to grow by 59.3% per annum.

Key information

42.1%

Earnings growth rate

59.3%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	59.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	20 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:2UV - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	155	-73	N/A	N/A	3
12/31/2025	57	-88	N/A	N/A	4
12/31/2024	1	-180	N/A	N/A	3
9/30/2024	0	-187	-82	-82	N/A
6/30/2024	0	-161	-73	-73	N/A
3/31/2024	0	-194	-67	-67	N/A
12/31/2023	10	-120	-55	-55	N/A
9/30/2023	11	-97	-54	-54	N/A
6/30/2023	11	-73	-59	-59	N/A
3/31/2023	11	-70	-61	-61	N/A
12/31/2022	N/A	-83	-78	-78	N/A
9/30/2022	N/A	-95	-89	-89	N/A
6/30/2022	N/A	-105	-85	-85	N/A
3/31/2022	N/A	-105	-93	-93	N/A
12/31/2021	N/A	-106	-91	-91	N/A
9/30/2021	N/A	-102	-87	-87	N/A
6/30/2021	N/A	-104	-92	-92	N/A
3/31/2021	N/A	-106	-82	-82	N/A
12/31/2020	N/A	-94	-78	-78	N/A
9/30/2020	N/A	-88	-68	-68	N/A
6/30/2020	N/A	-69	-55	-55	N/A
3/31/2020	N/A	-49	-48	-48	N/A
12/31/2019	N/A	-46	-36	-36	N/A
9/30/2019	N/A	-35	-30	-30	N/A
6/30/2019	N/A	-28	-24	-24	N/A
3/31/2019	N/A	-23	-17	-17	N/A
12/31/2018	N/A	-17	-11	-11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2UV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2UV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2UV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2UV's revenue (59% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 2UV's revenue (59% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 2UV's Return on Equity is forecast to be high in 3 years time

Applied Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

Forecast to breakeven in 2026

Recent updates

New major risk - Financial position

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

Chief Medical Officer recently sold €119k worth of stock

Chair of the Board of Directors recently sold €4.3m worth of stock

No longer forecast to breakeven

New minor risk - Profitability

New major risk - Share price stability

Chair of the Board of Directors recently sold €245k worth of stock

New minor risk - Profitability

Forecast to breakeven in 2026

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

Chair of the Board of Directors recently sold €1.6m worth of stock

New major risk - Revenue and earnings growth

Applied Therapeutics, Inc. announced that it expects to receive $99.997998 million in funding from a group of investors

Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial

Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Insufficient new directors

Applied Therapeutics, Inc. Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

Independent Director recently bought €60k worth of stock

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

New major risk - Shareholder dilution

New major risk - Financial position

Applied Therapeutics Announces Positive Sorbitol Reduction Data from the Ongoing Phase 3 Inspire Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Insufficient new directors

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

Applied Therapeutics, Inc. Announces Positive Data Trend in AT-007 Action-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format

Insufficient new directors

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies